Chinese TCM pharma company known for Naoxintong and other cerebro/cardiovascular traditional-medicine products.
Chinese TCM pharma company known for Naoxintong and other cerebro/cardiovascular traditional-medicine products.
Relies on a single brand franchise, Naoxintong, sold through hospitals and drugstores under national reimbursement listing. It markets heavily to doctors and pharmacy chains, so selling expenses are the main cost. Founder-controlled.
Moat: narrow (brand). Well-known branded TCM formula for stroke/cardiovascular care with established physician trust.
Headquarters: Shandong, China · Employees: 7,237
Size Shandong Buchang Pharmaceuticals (603858.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.25B, the 1068th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.68 on 18 Nov 2026.
Performance Over six months the shares fell 7.2%, against -5.0% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 4.2% over the last twelve months (peer median +5.1%); the operating margin is 9.8% (peer median 13.9%).
Valuation It trades at 1.5× enterprise value to sales against a peer median of 3.8× (2nd cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.8 points above its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥11.4B | CN¥11.8B | CN¥10.9B | CN¥13.1B | CN¥14.8B |
| Revenue growth | — | +8% | -17% | -11% | — |
| Gross profit | CN¥7.25B | CN¥7.21B | CN¥6.17B | CN¥8.57B | CN¥10.2B |
| EBITDA | n/a | CN¥1.69B | CN¥1.30B | CN¥1.65B | CN¥2.30B |
| Net income | CN¥282M | CN¥361M | -CN¥554M | CN¥319M | -CN¥1.53B |
| Free cash flow | CN¥784M | CN¥1.05B | CN¥753M | -CN¥694M | CN¥2.24B |
| Capital expenditure | CN¥196M | CN¥123M | CN¥197M | CN¥530M | CN¥543M |
| Total debt | CN¥4.11B | CN¥3.86B | CN¥3.76B | CN¥3.41B | CN¥3.39B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Shandong Buchang Pharmaceuticals 603858.SS | $2.25B | -7% | +4% | 10% | 1.5× | -2.5% |
| Tasly Pharmaceutical 600535.SS | $3.19B | -2% | -4% | 19% | 2.2× | -7.5% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | $3.83B | -7% | +32% | 21% | 2.9× | -3.9% |
| Jiangsu Kanion Pharmaceutical 600557.SS | $989M | -9% | +8% | 7% | 1.4× | 2.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603858.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.1% | -5.5% | 6th highest of 21 |
| 6-month return | -7.2% | -5.0% | 11th highest of 21 |
| Distance from 52-week high | -20.5% | -29.6% | 7th highest of 21 |
| Revenue growth (TTM) | +4.2% | +5.1% | 9th lowest of 20 |
| Operating margin | 9.8% | 13.9% | 8th lowest of 19 |
| EV / Sales | 1.5× | 3.8× | 2nd cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -2.5% | 3.3% | 5th least demanding of 17 |
| Growth delivered (Del g) | -5.8% | +8.5% | lowest of 17 |
| Hurdle (Req g minus delivered) | +3.3 pp | -0.9 pp | 6th most demanding of 17 |
| ROIC minus cost of capital | +3.8 pp | -0.4 pp | 5th highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | 1.5× | -2.5% | -5.8% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 2.6× | 26.7% | +6.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 4.2× | 0.9% | +0.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 1.7× | -9.7% | -1.5% |
| Acrobiosystems 301080.SZ | China | $2.31B | +65% | +29% | 17% | 14.0× | 41.3% | +27.7% |
| Regencell Bioscience RGC | United States | $2.33B | -83% | n/a | n/a | n/a | n/a | n/a |
| Perrigo PRGO | United States | $2.35B | +52% | -4% | 5% | 1.3× | 14.1% | +0.8% |
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.36B | -66% | +23% | 7% | 11.8× | n/a | n/a |
| NewAmsterdam Pharma NAMS | United States | $2.37B | -45% | -26% | -900% | 67.0× | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.38B | +14% | -9% | -6% | 2.0× | 47.0% | +19.3% |
| Keymed Biosciences 2162.HK | Hong Kong | $2.39B | +7% | 0% | -73% | 16.8× | n/a | n/a |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.40B | -33% | +153% | -7% | 13.6× | 37.9% | +22.9% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 3.8× | 2.3% | +2.9% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 4.0× | -11.0% | +37.6% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 8.4× | 3.2% | +15.7% |
| InnoCare Pharma 688428.SS | China | $2.07B | -7% | +135% | 35% | 2.8× | -10.9% | +344.2% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 1.9× | 6.1% | +6.5% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 3.3× | -4.7% | +10.6% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 3.2× | 5.1% | +6.4% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 4.2× | 3.4% | +4.8% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 2.4× | 1.7% | +15.7% |